NCT03012672View on ClinicalTrials.gov

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 30, 2016

Primary Completion Date

December 10, 2020

Study Completion Date

February 26, 2021

Conditions
Acute Leukemia of Ambiguous LineageAcute Myeloid LeukemiaMyeloid Neoplasm
Interventions
DRUG

Cladribine

Given IV

DRUG

Cytarabine

Given IV

BIOLOGICAL

Granulocyte Colony-Stimulating Factor

Given SC

DRUG

Mitoxantrone Hydrochloride

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT03012672 - Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm | Biotech Hunter | Biotech Hunter